Austrian deep-tech startup develops next-generation cell therapy manufacturing platform
Sarcura closes an oversubscribed €7M Seed Plus funding round: “If successful, they could completely change the cancer treatment landscape"
21-Nov-2022 -
The round was co-led by seed investors Lansdowne Investment Company Cyprus and IST Cube with participation from newly joined HCVC and tecnet equity. Besides returning seed investors Axilium Holding, Novacapital, and Nina CapitalSarcura is particularly happy to welcome newly joined European ...
cancer
cell therapies
prototypes
+1